DK1381611T3 - Metalsubstituerede ikke-centrosymmetriske phthalocyaninanaloger, fremstilling heraf og anvendelse i fotodynamisk terapi samt in vivo diagnostik - Google Patents

Metalsubstituerede ikke-centrosymmetriske phthalocyaninanaloger, fremstilling heraf og anvendelse i fotodynamisk terapi samt in vivo diagnostik

Info

Publication number
DK1381611T3
DK1381611T3 DK02750855T DK02750855T DK1381611T3 DK 1381611 T3 DK1381611 T3 DK 1381611T3 DK 02750855 T DK02750855 T DK 02750855T DK 02750855 T DK02750855 T DK 02750855T DK 1381611 T3 DK1381611 T3 DK 1381611T3
Authority
DK
Denmark
Prior art keywords
phthalocyanine
useful
photodynamic therapy
carriers
vivo
Prior art date
Application number
DK02750855T
Other languages
English (en)
Inventor
Gabrio Roncucci
Donata L Dei
Filippis Maria De
Lia Fantetti
Daniele Nistri
Original Assignee
Molteni & C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molteni & C filed Critical Molteni & C
Application granted granted Critical
Publication of DK1381611T3 publication Critical patent/DK1381611T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK02750855T 2001-03-21 2002-03-20 Metalsubstituerede ikke-centrosymmetriske phthalocyaninanaloger, fremstilling heraf og anvendelse i fotodynamisk terapi samt in vivo diagnostik DK1381611T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01106411 2001-03-21
PCT/EP2002/003108 WO2002090361A1 (en) 2001-03-21 2002-03-20 Metal substituted non centrosimmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostic

Publications (1)

Publication Number Publication Date
DK1381611T3 true DK1381611T3 (da) 2005-10-24

Family

ID=8176785

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02750855T DK1381611T3 (da) 2001-03-21 2002-03-20 Metalsubstituerede ikke-centrosymmetriske phthalocyaninanaloger, fremstilling heraf og anvendelse i fotodynamisk terapi samt in vivo diagnostik

Country Status (14)

Country Link
US (1) US7153841B2 (da)
EP (1) EP1381611B1 (da)
JP (1) JP2004529171A (da)
CN (1) CN100351255C (da)
AT (1) ATE298341T1 (da)
AU (1) AU2002341034B2 (da)
CA (1) CA2441386C (da)
DE (1) DE60204767T2 (da)
DK (1) DK1381611T3 (da)
ES (1) ES2244793T3 (da)
IL (2) IL158032A0 (da)
PT (1) PT1381611E (da)
WO (1) WO2002090361A1 (da)
ZA (1) ZA200308093B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1362844T3 (da) 2001-01-26 2008-04-14 Btg Int Ltd Benzylaminanalog
DE60205085T2 (de) 2002-04-25 2006-04-20 L. Molteni & C. dei Fratelli Alitti Società di Esercizio S.p.A. Metallphthalocyanin-analoge enthaltende antibakterielle Zusammensetzungen
ITFI20020200A1 (it) 2002-10-21 2004-04-22 Molteni & C Dei Flii Alitti S P A Societa L Porfirine meso-sostituite.
ITFI20050093A1 (it) * 2005-05-05 2006-11-06 Molteni & C Processo per la preparazione di cloruri di derivati ftalocianinici comprendenti almeno un gruppo ammonio quaternario
ITFI20050092A1 (it) 2005-05-05 2006-11-06 Molteni & C Derivati ftalocianinici, processo per la loro preparazione, composizioni farmaceutiche che li contengono e loro uso
EP1904109B1 (en) * 2005-06-29 2013-04-03 L. MOLTENI & C. dei Fratelli Alitti Società' di Esercizio S.p.A. Self-sterilizing products
WO2007009101A2 (en) * 2005-07-14 2007-01-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Tetraazaporphyrin-based compounds and their uses
CN1939919B (zh) * 2005-09-30 2010-06-09 中国科学院福建物质结构研究所 一种广谱、低毒性的酞菁类杀菌剂及其制备方法和用途
GB0520436D0 (en) * 2005-10-07 2005-11-16 Photobiotics Ltd Biological materials and uses thereof
EP2072584B1 (de) 2007-12-17 2011-05-11 ILFORD Imaging Switzerland GmbH Phthalocyanin-Farbstoffe, ihre Herstellung und Verwendung
US9040687B2 (en) * 2010-01-22 2015-05-26 Council Of Scientific And Idustrial Research Process for the preparaton of novel porphyrin derivatives and their use as PDT agents and fluorescence probes
WO2012086857A1 (ko) * 2010-12-21 2012-06-28 (주)파낙스이엠 광역학 진단 또는 치료를 위한 결합체 및 이의 제조방법
ITFI20110166A1 (it) * 2011-08-05 2013-02-06 Molteni & C Nuovi fotosensibilizzanti ad uso terapeutico.
CN103382205B (zh) * 2012-05-03 2015-10-28 中国医学科学院生物医学工程研究所 骨靶向的酞菁锌及制备方法及用途
KR101933620B1 (ko) * 2012-09-18 2018-12-28 삼성전자주식회사 소포를 검출하기 위한 조성물, 키트 및 이를 이용하여 소포를 분석하는 방법
RS65324B1 (sr) 2013-10-18 2024-04-30 Novartis Ag Obeleženi inhibitori membranskog antigena specifičnog za prostatu (psma), njihova upotreba kao agenasa za snimanje i farmaceutskih agenasa za lečenje karcinoma prostate
JP6269946B2 (ja) * 2014-03-25 2018-01-31 国立大学法人名古屋大学 細菌の増殖抑制
CN104262350B (zh) * 2014-10-09 2017-01-18 福州大学 一种酞菁金属配合物及其制备方法和应用
CN105418643B (zh) * 2015-12-22 2017-10-20 福州大学 一种双边生物素‑酞菁锌轭合物及其制备和应用
CN106866721B (zh) * 2017-03-10 2019-03-26 江苏省原子医学研究所 一种硅酞菁衍生物及其制备生物素受体靶向硅酞菁光敏剂的应用
CN108498855B (zh) * 2018-05-09 2021-04-27 福州大学 一种抗菌止血溶胶及其制备方法
WO2021261546A1 (ja) * 2020-06-24 2021-12-30 国立大学法人 東京大学 光増感色素
CN112409365B (zh) * 2020-12-09 2021-11-02 福州大学 3-磺酸基丙烷巯基修饰酞菁及其制备方法与在制药领域的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0434727A4 (en) * 1988-09-08 1994-08-17 Ultra Diagnostic Corp Red-shifted phthalocyanine and tetrabenztriazaporphyrin reagents
JPH0672873A (ja) * 1992-08-27 1994-03-15 Nippon Shokubai Co Ltd 腫瘍治療剤および腫瘍光化学診断薬
GB9405970D0 (en) * 1994-03-25 1994-05-11 Secr Defence Substituted phthalocyanines
CN1053906C (zh) * 1996-10-15 2000-06-28 福州大学 酞菁锌配合物及其制造方法和在制抗癌药中的应用
DE19731741A1 (de) * 1997-07-23 1999-01-28 Deutsches Krebsforsch Konjugat zur Unterscheidung von krankhaftem und gesundem Gewebe
IT1294325B1 (it) * 1997-08-14 1999-03-24 Molteni L E C Dei Fratelli Ali Zinco-ftalocianine e relativi coniugati, preparazione e uso nella terapia fotodinamica e come diagnostici
CZ20021974A3 (cs) * 1999-12-08 2002-11-13 Gentian As Substituované ftalocyaniny, způsob jejich výroby a farmaceutický prostředek obsahující tyto sloučeniny
JP4139539B2 (ja) * 2000-01-21 2008-08-27 富士フイルム株式会社 光重合性画像記録材料及び平版印刷版原版
PT1164135E (pt) * 2000-06-15 2004-06-30 Molteni & C Frat Alitti Soc Es Metal-ftalocianinas substituidas sua preparacao e utilizacao

Also Published As

Publication number Publication date
ZA200308093B (en) 2004-07-08
EP1381611A1 (en) 2004-01-21
IL158032A0 (en) 2004-03-28
AU2002341034B2 (en) 2007-06-14
US20040156787A1 (en) 2004-08-12
WO2002090361A1 (en) 2002-11-14
PT1381611E (pt) 2005-11-30
CA2441386A1 (en) 2002-11-14
ES2244793T3 (es) 2005-12-16
CA2441386C (en) 2010-12-21
DE60204767T2 (de) 2006-05-18
IL158032A (en) 2009-09-01
DE60204767D1 (de) 2005-07-28
WO2002090361A8 (en) 2004-05-21
CN100351255C (zh) 2007-11-28
EP1381611B1 (en) 2005-06-22
CN1633437A (zh) 2005-06-29
JP2004529171A (ja) 2004-09-24
ATE298341T1 (de) 2005-07-15
US7153841B2 (en) 2006-12-26

Similar Documents

Publication Publication Date Title
DK1381611T3 (da) Metalsubstituerede ikke-centrosymmetriske phthalocyaninanaloger, fremstilling heraf og anvendelse i fotodynamisk terapi samt in vivo diagnostik
Hamblin et al. Can light‐based approaches overcome antimicrobial resistance?
Spikes et al. Photodynamic therapy of tumours and other diseases using porphyrins
Chan et al. Cell uptake, distribution and response to aluminium chloro sulphonated phthalocyanine, a potential anti-tumour photosensitizer
Vahabi et al. The effect of antimicrobial photodynamic therapy with radachlorin and toluidine blue on streptococcus mutans: an in vitro study
CY1120977T1 (el) Θεραπεια των ασθενειων αποθηκευσης γλυκογονου τυπου ιι
ATE387450T1 (de) Meso-substituierte porphyrine
Kostron et al. Photodynamic medicine: From bench to clinic
ES2174215T3 (es) Complejos metalicos que contienen perfluoro-alquilo y su utilizacion en el diagnostico por nmr.
DE60029944D1 (de) Polyamine und ihre therapeutische verwendung
ATE259814T1 (de) Substituierte metallphthalocyaninen, ihre herstellung und verwendung
WO2005030254A3 (en) Conjugates for photodynamic therapy
PT1420824E (pt) Clorinas sulfonadas como fotossensibilizadores
DK0906758T3 (da) Zink-phthalocyaniner og tilsvarende konjugater, deres frembingelse og anvendelse i fotodynamisk terapi og som diagnostiske midler
Cheng et al. Photoradiation therapy: current status and applications in the treatment of brain tumors
Gharesi et al. Effect of photodynamic therapy based on indocyanine green on expression of apoptosis-related genes in human gingival fibroblast cells
Wainwright et al. Comparative photodynamic evaluation of new phenothiazinium derivatives against Propionibacterium acnes
Zhang et al. Electron spin resonance studies on photosensitized formation of hydroxyl radical by C-phycocyanin from Spirulina platensis
Przygoda et al. Cellular Mechanisms of Singlet Oxygen in Photodynamic Therapy
WO2005048944A3 (en) Activatable photodynamic therapy agents
PL365279A1 (en) Biotin-derivates and their conjugates with chelating agents
DE602004030661D1 (de) Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
Songca et al. Photodynamic therapy: A new light for the developing world
RU2345803C2 (ru) Способ фотоиммунотерапии фотосенсибилизатором, активируемым волновой энергией вне организма человека
Songca Combinations of Photodynamic Therapy against Cancer and Microbial Infections